Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s rare blood disorder drug Cablivi set for European approval

Sanofi’s rare blood disorder drug Cablivi set for European approval

The EMA’s Committee for Medicinal Products for Human Use (CHMP) gave its blessing to Cablivi (caplacizumab) at its monthly meeting last week, along with three other rare disease therapies, two

Latest news

  • Sanofi poaches Peugeot's finance head Sanofi poaches Peugeot's finance head

    It also made a play for nanobody focused biopharma Ablynx, which it acquired for 3.9bn, along with its lead candidate and orphan drug caplacizumab for rare blood disorder acquired thrombotic

  • Sanofi appoints ex-Roche Reed as new R&D head Sanofi appoints ex-Roche Reed as new R&D head

    Sanofi currently has just one drug pending FDA approval - Ablynx’s caplacizumab, a new treatment for blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP), but needs more filings over the next

  • Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

    With operating conditions increasingly tough for its core diabetes franchise as well, Novo has been trying to grow its pipeline, but an attempt to buy Ablynx and its lead product caplacizumab

  • Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

    Both deals boost its positions in rare diseases and haematology, with Ablynx’lead product caplacizumab acquired thrombotic thrombocytopenic purpura (aTTP) slotting neatly into Sanofi’s pipeline along with the Bioverativ haemophilia ... Geel.

  • Ablynx knocks-back Novo Nordisk’s second bid Ablynx knocks-back Novo Nordisk’s second bid

    Ablynx has rejected Novo Nordisk’s proposal to acquire the Belgian biopharma and its lead candidate caplacizumab, stating that the deal wouldn’t be in the “best interests of the company”. ... However Ablynx - whose long-term plan is to become a

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Strategically caplacizumab represented a good fit for Novo Nordisk as it complements the company's portfolio of products focused on haemophilia. ... Acquisition company. 7, 000. Ablynx/Sanofi. Nanobody platform product pipeline; lead product caplacizumab

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Quick links

Infographics

Multimedia